Get the Stockscreener App
5.86
3.73%
0.14
Evoke Pharma Inc stock is traded at $5.86, with a volume of 107.23K.
It is up +3.73% in the last 24 hours and up +13.02% over the past month.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
See More
Previous Close:
$5.72
Open:
$5.58
24h Volume:
107.23K
Relative Volume:
0.26
Market Cap:
$4.50M
Revenue:
$5.18M
Net Income/Loss:
$-7.79M
P/E Ratio:
-2.4831
EPS:
-2.36
Net Cash Flow:
$-4.99M
1W Performance:
-5.82%
1M Performance:
+13.02%
6M Performance:
+1.85%
1Y Performance:
-58.45%
1-Day Range:
$5.31
$6.0499
1-Week Range:
$5.3042
$6.71
52-Week Range:
$3.54
$17.88
Evoke Pharma Inc Stock (EVOK) Company Profile
Name
Evoke Pharma Inc
Sector
Phone
858-345-1494
Address
420 STEVENS AVENUE, SOLANA BEACH, CA
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-22-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-05-19 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-08-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Oct-19-17 | Resumed | FBR & Co. | Buy |
| Mar-16-17 | Reiterated | Rodman & Renshaw | Buy |
| Jan-30-17 | Upgrade | Laidlaw | Neutral → Buy |
| Jan-05-17 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Dec-23-16 | Reiterated | Rodman & Renshaw | Neutral |
| Jul-19-16 | Reiterated | FBR Capital | Outperform |
| Jul-19-16 | Downgrade | Noble Financial | Buy → Hold |
| Jul-18-16 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Mar-16-16 | Initiated | Northland Capital | Outperform |
| Mar-14-16 | Reiterated | Ascendiant Capital Markets | Buy |
| Feb-17-16 | Resumed | FBR Capital | Outperform |
| Dec-03-14 | Reiterated | MLV & Co | Buy |
| Nov-07-14 | Initiated | MLV & Co | Buy |
| Apr-22-14 | Initiated | Laidlaw | Buy |
| Nov-19-13 | Initiated | Aegis Capital | Buy |
View All
Evoke Pharma Inc Stock (EVOK) Latest News
Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit - Yahoo Finance
Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World
Global Digestive Health Market Size, Share And Growth Analysis For 2024-2033 - EIN News
Canopy Growth Corporation (CGC) Stock Price, News, Quote & History - Yahoo Finance
Evoke Pharma (FRA:EV0) Enterprise Value : €1.02 Mil (As of Nov. 01, 2024) - GuruFocus.com
Gastroparesis Treatment Market Top Trends and Growth Analysis: - openPR
When Will Evoke Pharma, Inc. (NASDAQ:EVOK) Become Profitable? - Simply Wall St
Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
Five things for pharma marketers to know for Tuesday morning - MM+M Online
Evoke Pharma holds Buy rating with $18 target from Laidlaw - Investing.com
S&P 500 Moves Higher; Philips Shares Plunge After Q3 EarningsKoninklijke Philips (NYSE:PHG) - Benzinga
Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention - Barchart
Evoke Pharma Shares Soar on Positive Data for Gimoti Nasal Treatment in Diabetic Gastroparesis - Yahoo Finance
What made Evoke Pharma stock more than double on Monday? - Invezz
Crude Oil Tumbles Over 5%; Autonomix Medical Shares Spike Higher - Benzinga
Evoke Pharma Shares Rise 70% on Gimoti Data in GLP-1 Users - MarketWatch
Evoke stock rockets 90% on study of Gimoti in GLP-1 users (NASDAQ:EVOK) - Seeking Alpha
Dow Jumps Over 300 Points; ON Semiconductor Earnings Top ViewsHealthcare Triangle (NASDAQ:HCTI) - Benzinga
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Evoke Pharma Stock Is Soaring Monday: What's Going On? - Benzinga
Evoke Pharma reports significant benefits of GIMOTI in DGP study - Investing.com India
Evoke Pharma & EVERSANA Announce Statistically Significant - GlobeNewswire
Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI® - StockTitan
Gastroparesis Drugs Market: Size, Share, Trends, and Forecast for 2024-2033 - openPR
Global Manufacturer and Distributor Chooses Bridgeline's AI-Powered HawkSearch - The Manila Times
Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting - The Manila Times
Evoke Pharma to Showcase Award-Winning Research at the 2024 - GlobeNewswire
Evoke Pharma appoints Benjamin Smeal as new director By Investing.com - Investing.com Canada
Evoke Pharma appoints Benjamin Smeal as new director - Investing.com India
Evoke Pharma Appoints Benjamin Smeal as Director - TipRanks
Evoke Pharma, Inc. Appoints Benjamin Smeal to Serve as Class II Director - Marketscreener.com
Evoke Pharma appoints new board member Ben Smeal - Investing.com India
Sky Quarry to Present at The ThinkEquity Conference on Wednesday, October 30, 2024 - The Manila Times
Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors - GlobeNewswire
iRobot (NASDAQ:IRBT) Raised to Hold at StockNews.com - Defense World
Evoke Pharma secures lease extension for headquarters - Investing.com India
(EVOK) Technical Data - Stock Traders Daily
Evoke Pharma secures lease extension for headquarters By Investing.com - Investing.com Canada
Digestive and Intestinal Remedies Market Growth Analysis with Investment Opportunities For 2024-2033 - EIN News
Gastroparesis Drugs Market Opportunities, Challenges, - openPR
Breakthroughs in Diabetic Gastroparesis Treatment: What to Expect in 2024 - WhaTech
South Korea Posture Correction Market Size & Outlook, 2030 - Grand View Research
Gastroparesis Market Expected to Experience Major Growth - openPR
Gastroparesis Treatment Market Size, Demand, Trends, Analysis - openPR
Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com - Defense World
Evoke Pharma secures $3 million from warrant exercises - Investing.com
Scorpio Tankers Announces Vessel Sale Agreement - The Manila Times
Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion - GlobeNewswire
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
Evoke Pharma amends warrants, secures $2.4 million funding By Investing.com - Investing.com South Africa
Evoke Pharma amends warrants, secures $2.4 million funding - Investing.com
Evoke Pharma Inc Stock (EVOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):